Clinical Scorecard: Study Supports 30-Second Chlorhexidine Protocol for IVI
At a Glance
| Category | Detail |
|---|---|
| Condition | Intravitreal Injection Antisepsis |
| Key Mechanisms | Reduction of conjunctival bacteria using aqueous chlorhexidine 0.05% |
| Target Population | Patients undergoing intravitreal injections |
| Care Setting | Ophthalmology clinics performing IVIs |
Key Highlights
- 30 seconds of aqueous chlorhexidine 0.05% significantly reduced conjunctival bacteria.
- Reduction in culture positivity from 67.5% to 12.5% in the 30-second group.
- No adverse events such as infectious endophthalmitis or corneal toxicity observed.
- Aqueous chlorhexidine may cause less ocular discomfort compared to povidone-iodine.
- Study supports a standardized 30-second exposure protocol before IVI.
Guideline-Based Recommendations
Diagnosis
Management
- Use 0.05% aqueous chlorhexidine for antisepsis before intravitreal injections.
Monitoring & Follow-up
Risks
- Potential discomfort associated with povidone-iodine.
Patient & Prescribing Data
Patients receiving intravitreal injections in retina practices.
Aqueous chlorhexidine 0.05% is effective and less irritating than povidone-iodine.
Clinical Best Practices
- Implement a 30-second exposure protocol for aqueous chlorhexidine before IVI.
Related Resources & Content
- Prophylaxis for endophthalmitis following intravitreal injection
- Aqueous chlorhexidine compared with povidone-iodine as ocular antisepsis
- Endophthalmitis after anti-VEGF intravitreal injections
- Povidone-iodine contact time and lid speculum use during intravitreal injection
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.